Feprazone Displays Antiadipogenesis and Antiobesity Capacities in in Vitro 3 T3-L1 Cells and in Vivo Mice.
Journal
ACS omega
ISSN: 2470-1343
Titre abrégé: ACS Omega
Pays: United States
ID NLM: 101691658
Informations de publication
Date de publication:
16 Mar 2021
16 Mar 2021
Historique:
received:
09
11
2020
accepted:
09
02
2021
entrez:
22
3
2021
pubmed:
23
3
2021
medline:
23
3
2021
Statut:
epublish
Résumé
Excessive lipid accumulation in adipose tissues and deregulation of adipogenesis-induced obesity affect millions of people worldwide. Feprazone, a nonsteroidal anti-inflammatory drug, has a wide clinical use. However, it is unknown whether Feprazone possesses an antiadipogenic ability. The aim of this study is to investigate whether Feprazone possesses an antiadipogenic ability in 3 T3-L1 cells and an antiobesity capacity in mouse models. An MTT assay was used to determine the optimized incubation concentrations of Feprazone in 3 T3-L1 cells. The lipid accumulation was evaluated using Oil Red O staining. The concentrations of triglyceride and glycerol release were detected to check the lipolysis during 3 T3-L1 adipogenesis. A quantitative real-time polymerase chain reaction (qRT-PCR) was used to determine the expressions of sterol regulatory element-binding protein-1C (SREBP-1C) and fatty acid binding protein 4 (FABP4) in treated cells. The expressions of peroxisome proliferator-activated receptor-γ (PPAR-γ), CCAAT/enhancer-binding protein α (C/EBP-α), adipose triglyceride lipase (ATGL), and aquaporin-7 (AQP-7) were detected using qRT-PCR and Western blot analysis. After the high-fat diet (HFD) mice were treated with Feprazone, the pathological state of adipocyte tissues was evaluated using HE staining. The adipocyte size, visceral adipocyte tissue weight, and bodyweights were recorded. According to the proliferation result, 30 and 60 μM Feprazone were used as the optimized concentrations of Feprazone. In the in vitro study, lipid accumulation, elevated production of triglycerides, the release of glycerol, upregulated SREBP-1C, FABP4, PPAR-γ, and C/EBP-α and downregulated ATGL and AQP-7 in the 3 T3-L1 adipocytes induced by the adipocyte differentiation cocktail medium were significantly reversed by treatment with Feprazone. In the in vivo experiment, we found that the increased adipocyte size, visceral adipocyte tissue weight, and body weights induced by HFD feeding in mice were significantly suppressed by the administration of Feprazone. Feprazone might display anti-adipogenic and antiobesity capacities in in vitro 3 T3-L1 cells and in vivo mice.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Excessive lipid accumulation in adipose tissues and deregulation of adipogenesis-induced obesity affect millions of people worldwide. Feprazone, a nonsteroidal anti-inflammatory drug, has a wide clinical use. However, it is unknown whether Feprazone possesses an antiadipogenic ability. The aim of this study is to investigate whether Feprazone possesses an antiadipogenic ability in 3 T3-L1 cells and an antiobesity capacity in mouse models.
METHODS
METHODS
An MTT assay was used to determine the optimized incubation concentrations of Feprazone in 3 T3-L1 cells. The lipid accumulation was evaluated using Oil Red O staining. The concentrations of triglyceride and glycerol release were detected to check the lipolysis during 3 T3-L1 adipogenesis. A quantitative real-time polymerase chain reaction (qRT-PCR) was used to determine the expressions of sterol regulatory element-binding protein-1C (SREBP-1C) and fatty acid binding protein 4 (FABP4) in treated cells. The expressions of peroxisome proliferator-activated receptor-γ (PPAR-γ), CCAAT/enhancer-binding protein α (C/EBP-α), adipose triglyceride lipase (ATGL), and aquaporin-7 (AQP-7) were detected using qRT-PCR and Western blot analysis. After the high-fat diet (HFD) mice were treated with Feprazone, the pathological state of adipocyte tissues was evaluated using HE staining. The adipocyte size, visceral adipocyte tissue weight, and bodyweights were recorded.
RESULTS
RESULTS
According to the proliferation result, 30 and 60 μM Feprazone were used as the optimized concentrations of Feprazone. In the in vitro study, lipid accumulation, elevated production of triglycerides, the release of glycerol, upregulated SREBP-1C, FABP4, PPAR-γ, and C/EBP-α and downregulated ATGL and AQP-7 in the 3 T3-L1 adipocytes induced by the adipocyte differentiation cocktail medium were significantly reversed by treatment with Feprazone. In the in vivo experiment, we found that the increased adipocyte size, visceral adipocyte tissue weight, and body weights induced by HFD feeding in mice were significantly suppressed by the administration of Feprazone.
CONCLUSION
CONCLUSIONS
Feprazone might display anti-adipogenic and antiobesity capacities in in vitro 3 T3-L1 cells and in vivo mice.
Identifiants
pubmed: 33748580
doi: 10.1021/acsomega.0c05470
pmc: PMC7970497
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6674-6680Informations de copyright
© 2021 The Authors. Published by American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Vitam Horm. 2012;90:143-62
pubmed: 23017715
J Nutr Biochem. 2013 Apr;24(4):613-23
pubmed: 23498665
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Arzneimittelforschung. 1972 Jan;22(1):Suppl 1a:196+
pubmed: 5067191
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):43-7
pubmed: 14688407
World J Gastroenterol. 2019 Mar 28;25(12):1492-1501
pubmed: 30948912
J Biol Chem. 1997 Feb 28;272(9):5367-70
pubmed: 9102400
Mol Cell. 1999 Oct;4(4):611-7
pubmed: 10549292
Genes Dev. 1999 Sep 1;13(17):2231-41
pubmed: 10485846
Food Funct. 2015 Sep;6(9):2939-48
pubmed: 26190448
Cell Metab. 2014 Aug 5;20(2):199-201
pubmed: 25100058
Compr Physiol. 2017 Mar 16;7(2):635-674
pubmed: 28333384
Exp Biol Med (Maywood). 2016 Mar;241(5):449-56
pubmed: 26645953
Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):873-7
pubmed: 8570651
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4333-7
pubmed: 9539737
Biochem J. 2007 Mar 15;402(3):591-600
pubmed: 17313375
Am J Clin Nutr. 2010 Jan;91(1):5-6
pubmed: 19939981
Trends Endocrinol Metab. 2008 Mar;19(2):65-73
pubmed: 18291668
Cell Metab. 2006 Oct;4(4):263-73
pubmed: 17011499
Mol Cell Endocrinol. 2010 Apr 29;318(1-2):61-8
pubmed: 19772894
J Endocrinol. 1999 Apr;161(1):89-97
pubmed: 10194532
Mol Aspects Med. 2012 Feb;33(1):26-34
pubmed: 22040698
Curr Protein Pept Sci. 2017;19(2):221-233
pubmed: 28925902
J Biol Chem. 2000 Jan 21;275(3):1873-7
pubmed: 10636887
Genes Dev. 1995 Jan 15;9(2):168-81
pubmed: 7531665
Am J Clin Nutr. 2010 Jan;91(1):280S-283S
pubmed: 19923373
Obes Rev. 2011 Jan;12(1):50-61
pubmed: 20059703
Int J Mol Med. 2017 Apr;39(4):969-983
pubmed: 28260070
EMBO J. 1997 Dec 15;16(24):7432-43
pubmed: 9405372
Int J Biochem Cell Biol. 2016 Dec;81(Pt A):57-66
pubmed: 27780754
J Investig Med. 2017 Dec;65(8):1102-1115
pubmed: 28947639
Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8757-61
pubmed: 8090719
Expert Rev Cardiovasc Ther. 2006 Nov;4(6):871-95
pubmed: 17173503
Chem Pharm Bull (Tokyo). 1986 Jan;34(1):214-20
pubmed: 3698130
Prog Cardiovasc Dis. 2018 Jul - Aug;61(2):142-150
pubmed: 29981771
J Agric Food Chem. 2019 Dec 11;67(49):13605-13616
pubmed: 31735033
Int J Mol Med. 2013 May;31(5):1166-76
pubmed: 23525347
Compr Physiol. 2017 Dec 12;8(1):1-8
pubmed: 29357123
Arzneimittelforschung. 1972 Jan;22(1):Suppl 1a:171-4
pubmed: 5067187
Front Immunol. 2018 Sep 20;9:2133
pubmed: 30294325